aspartic acid has been researched along with Chronic Disease in 91 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 7.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "Despite widely replicated abnormalities of gamma-aminobutyric acid (GABA) neurons in schizophrenia postmortem, few studies have measured tissue GABA levels in vivo." | 7.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "This in vivo (1)H magnetic resonance spectroscopy study examined levels of glutamate, glutamine, and N-acetylaspartate in medicated patients with chronic schizophrenia." | 7.72 | Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. ( Al-Semaan, Y; Densmore, M; Drost, DJ; Menon, RS; Neufeld, RW; Rajakumar, N; Schaefer, B; Théberge, J; Williamson, PC, 2003) |
| "The purpose of this study is to explore depression metabolic markers in rat hippocampus and to investigate the anti-depressant effect of genipin and its mechanisms using nuclear magnetic resonance (NMR) metabonomics." | 3.80 | [1H NMR based metabonomics study on the antidepressant effect of genipin in rat hippocampus]. ( Gao, S; Peng, GJ; Qin, XM; Shi, BY; Tian, JS, 2014) |
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 3.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "Despite widely replicated abnormalities of gamma-aminobutyric acid (GABA) neurons in schizophrenia postmortem, few studies have measured tissue GABA levels in vivo." | 3.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "Compared to controls, schizophrenia and bipolar patients presented decreased NAA to creatine ratios, while only the schizophrenia group showed an increase in CSF in the dorsolateral prefrontal region." | 3.74 | Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. ( Benito, C; Desco, M; Leal, I; Molina, V; Palomo, T; Rebolledo, R; Reig, S; Sánchez, J; Sanz, J; Sarramea, F, 2007) |
| "This in vivo (1)H magnetic resonance spectroscopy study examined levels of glutamate, glutamine, and N-acetylaspartate in medicated patients with chronic schizophrenia." | 3.72 | Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. ( Al-Semaan, Y; Densmore, M; Drost, DJ; Menon, RS; Neufeld, RW; Rajakumar, N; Schaefer, B; Théberge, J; Williamson, PC, 2003) |
| "In this study, cognitively intact chronic hypertensive older patients had a higher white matter myoinositol/creatine ratio compared with healthy older subjects, suggesting that myoinositol may be a sensitive marker of the effects of chronic hypertension on the brain." | 3.71 | Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. ( Benedetti, C; Catani, M; Cherubini, A; Howard, R; Mariani, E; Mecocci, P; Metastasio, A; Pelliccioli, GP; Senin, U; Tarducci, R, 2002) |
| " First, in patients with cerebral infarctions, increased concentrations of lactate were found in the majority of patients, and N-acetyl aspartate (NAA) was reduced to a significantly greater extent than choline (Cho) or creatine (Cre)." | 3.68 | Proton magnetic resonance spectroscopy of human brain: applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities. ( Calabrese, G; Deicken, R; Fein, G; Fisher, SN; Hetherington, HP; Sappey-Marinier, D; Van Dyke, C; Weiner, MW, 1992) |
| "Chronic visceral pain is frequent, extremely debilitating, and generally resistant to pharmacological treatment." | 2.76 | Clinical effects and brain metabolic correlates in non-invasive cortical neuromodulation for visceral pain. ( Dasilva, D; Freedman, SD; Fregni, F; Lenkinski, RE; Pascual-Leone, A; Potvin, K; Wang, X, 2011) |
| "Chronic migraine was associated with N-acetyl-aspartate reductions in the bilateral thalami and in the right anterior cingulate." | 1.48 | Neurochemical changes in the medial wall of the brain in chronic migraine. ( Chen, WT; Fuh, JL; Lai, KL; Lin, YR; Niddam, DM; Tsai, SY; Wang, SJ, 2018) |
| "Chronic smoking in alcohol dependence is associated with abnormalities in brain morphology and metabolite levels in large lobar regions (e." | 1.39 | Chronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system. ( Durazzo, TC; Gazdzinski, S; Meyerhoff, DJ; Mon, A, 2013) |
| "Acute-on-chronic liver failure (ACLF), acute liver failure (ALF) and chronic liver disease (CLD) are common forms of liver failure and present with similar clinical profiles." | 1.35 | In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure. ( Gupta, RK; Nath, K; Radha Krishna, Y; Saraswat, VA; Thomas, MA; Verma, A, 2008) |
| "Fourteen patients with chronic paranoid schizophrenia, 17 euthymic type I bipolar patients with no previous history of psychotic symptoms and 15 healthy controls were included, most of them were female." | 1.35 | Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder. ( Albert, C; Cabaleiro, F; de Luxan, A; Galán, R; Leal, I; Luque, R; Molina, V; Osuna, MI; Prieto, D; Ruiz, M; Sarramea Crespo, F; Sau, P, 2008) |
| "Carbon monoxide (CO) exposure is a common cause of toxic brain damage, whereby effects range from transient neurological dysfunction to coma and death." | 1.33 | Carbon monoxide brain toxicity: clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people. ( Prockop, LD, 2005) |
| "Gabapentin is an anticonvulsant that successfully treats many neuropathic pain syndromes, although the mechanism of its antihyperalgesic action remains elusive." | 1.33 | Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2005) |
| "47 patients were recruited with episodic cluster headache (35 in cluster period and 12 in remission), 21 normal controls, and 16 patients with chronic migraine." | 1.33 | Reduction in hypothalamic 1H-MRS metabolite ratios in patients with cluster headache. ( Chen, JJ; Fuh, JL; Lirng, JF; Wang, SJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (16.48) | 18.7374 |
| 1990's | 18 (19.78) | 18.2507 |
| 2000's | 41 (45.05) | 29.6817 |
| 2010's | 16 (17.58) | 24.3611 |
| 2020's | 1 (1.10) | 2.80 |
| Authors | Studies |
|---|---|
| Ferris, JK | 1 |
| Neva, JL | 1 |
| Vavasour, IM | 1 |
| Attard, KJ | 1 |
| Greeley, B | 1 |
| Hayward, KS | 1 |
| Wadden, KP | 1 |
| MacKay, AL | 1 |
| Boyd, LA | 1 |
| Niddam, DM | 1 |
| Lai, KL | 1 |
| Tsai, SY | 1 |
| Lin, YR | 1 |
| Chen, WT | 1 |
| Fuh, JL | 2 |
| Wang, SJ | 2 |
| Natsubori, T | 1 |
| Inoue, H | 1 |
| Abe, O | 1 |
| Takano, Y | 1 |
| Iwashiro, N | 1 |
| Aoki, Y | 1 |
| Koike, S | 1 |
| Yahata, N | 1 |
| Katsura, M | 1 |
| Gonoi, W | 1 |
| Sasaki, H | 1 |
| Takao, H | 1 |
| Kasai, K | 2 |
| Yamasue, H | 2 |
| Harezlak, J | 1 |
| Cohen, R | 1 |
| Gongvatana, A | 1 |
| Taylor, M | 1 |
| Buchthal, S | 1 |
| Schifitto, G | 1 |
| Zhong, J | 1 |
| Daar, ES | 1 |
| Alger, JR | 1 |
| Brown, M | 1 |
| Singer, EJ | 1 |
| Campbell, TB | 1 |
| McMahon, D | 1 |
| So, YT | 1 |
| Yiannoutsos, CT | 1 |
| Navia, BA | 1 |
| Peng, GJ | 1 |
| Shi, BY | 1 |
| Tian, JS | 1 |
| Gao, S | 1 |
| Qin, XM | 1 |
| Sierra-Paredes, G | 1 |
| Loureiro, AI | 1 |
| Wright, LC | 1 |
| Sierra-Marcuño, G | 1 |
| Soares-da-Silva, P | 1 |
| Franceschelli, A | 1 |
| Sens, J | 1 |
| Herchick, S | 1 |
| Thelen, C | 1 |
| Pitychoutis, PM | 1 |
| Zahr, NM | 1 |
| Carr, RA | 1 |
| Rohlfing, T | 1 |
| Mayer, D | 1 |
| Sullivan, EV | 1 |
| Colrain, IM | 1 |
| Pfefferbaum, A | 1 |
| DeSantana, JM | 1 |
| Sluka, KA | 1 |
| Sarmento, E | 1 |
| Moreira, P | 1 |
| Brito, C | 1 |
| Souza, J | 1 |
| Jevoux, C | 1 |
| Bigal, M | 1 |
| Yilmaz, E | 1 |
| Mir, S | 1 |
| Berdeli, A | 3 |
| Pajonk, FG | 1 |
| Wobrock, T | 1 |
| Gruber, O | 1 |
| Scherk, H | 1 |
| Berner, D | 1 |
| Kaizl, I | 1 |
| Kierer, A | 1 |
| Müller, S | 1 |
| Oest, M | 1 |
| Meyer, T | 1 |
| Backens, M | 1 |
| Schneider-Axmann, T | 1 |
| Thornton, AE | 1 |
| Honer, WG | 1 |
| Falkai, P | 1 |
| Ongür, D | 1 |
| Prescot, AP | 1 |
| McCarthy, J | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Xie, W | 1 |
| Yu, Y | 1 |
| Zhao, Y | 1 |
| Fregni, F | 1 |
| Potvin, K | 1 |
| Dasilva, D | 1 |
| Wang, X | 1 |
| Lenkinski, RE | 2 |
| Freedman, SD | 1 |
| Pascual-Leone, A | 1 |
| Lentz, MR | 2 |
| Degaonkar, M | 1 |
| Mohamed, MA | 1 |
| Kim, H | 1 |
| Conant, K | 1 |
| Halpern, EF | 1 |
| Sacktor, N | 1 |
| Barker, PB | 1 |
| Pomper, MG | 1 |
| Portella, MJ | 1 |
| de Diego-Adeliño, J | 1 |
| Gómez-Ansón, B | 1 |
| Morgan-Ferrando, R | 1 |
| Vives, Y | 1 |
| Puigdemont, D | 1 |
| Pérez-Egea, R | 1 |
| Ruscalleda, J | 1 |
| Pérez, V | 1 |
| Reismann, P | 1 |
| Durazzo, TC | 1 |
| Mon, A | 1 |
| Gazdzinski, S | 1 |
| Meyerhoff, DJ | 1 |
| Wang, WT | 1 |
| Lee, P | 1 |
| Yeh, HW | 1 |
| Smirnova, IV | 1 |
| Choi, IY | 1 |
| Catani, M | 1 |
| Mecocci, P | 1 |
| Tarducci, R | 1 |
| Howard, R | 1 |
| Pelliccioli, GP | 1 |
| Mariani, E | 1 |
| Metastasio, A | 1 |
| Benedetti, C | 1 |
| Senin, U | 1 |
| Cherubini, A | 1 |
| Roitberg, B | 1 |
| Khan, N | 1 |
| Tuccar, E | 1 |
| Kompoliti, K | 1 |
| Chu, Y | 1 |
| Alperin, N | 1 |
| Kordower, JH | 1 |
| Emborg, ME | 1 |
| Grachev, ID | 5 |
| Ramachandran, TS | 2 |
| Thomas, PS | 2 |
| Szeverenyi, NM | 1 |
| Fredrickson, BE | 2 |
| Demougeot, C | 1 |
| Bertrand, N | 1 |
| Prigent-Tessier, A | 1 |
| Garnier, P | 1 |
| Mossiat, C | 1 |
| Giroud, M | 1 |
| Marie, C | 1 |
| Beley, A | 1 |
| Lee, H | 1 |
| Holburn, GH | 1 |
| Price, RR | 1 |
| Fukui, S | 1 |
| Fukui, T | 1 |
| Fukuda, R | 1 |
| Iwanami, A | 1 |
| Kato, N | 1 |
| Kato, T | 1 |
| Théberge, J | 1 |
| Al-Semaan, Y | 1 |
| Williamson, PC | 2 |
| Menon, RS | 1 |
| Neufeld, RW | 1 |
| Rajakumar, N | 1 |
| Schaefer, B | 1 |
| Densmore, M | 1 |
| Drost, DJ | 2 |
| Fuller, RA | 1 |
| Westmoreland, SV | 1 |
| Ratai, E | 1 |
| Greco, JB | 1 |
| Kim, JP | 1 |
| He, J | 1 |
| Sehgal, PK | 1 |
| Masliah, E | 1 |
| Halpern, E | 1 |
| Lackner, AA | 1 |
| González, RG | 1 |
| Burneo, JG | 1 |
| Knowlton, RC | 1 |
| Faught, E | 1 |
| Martin, R | 1 |
| Sawrie, S | 1 |
| Kuzniecky, RI | 1 |
| Ohrmann, P | 2 |
| Siegmund, A | 2 |
| Suslow, T | 2 |
| Spitzberg, K | 2 |
| Kersting, A | 2 |
| Arolt, V | 2 |
| Heindel, W | 2 |
| Pfleiderer, B | 2 |
| Molina, V | 3 |
| Sánchez, J | 2 |
| Reig, S | 2 |
| Sanz, J | 2 |
| Benito, C | 2 |
| Santamarta, C | 1 |
| Pascau, J | 1 |
| Sarramea, F | 2 |
| Gispert, JD | 1 |
| Misiego, JM | 1 |
| Palomo, T | 2 |
| Desco, M | 2 |
| Chang, L | 1 |
| Ernst, T | 1 |
| Speck, O | 1 |
| Grob, CS | 1 |
| Prockop, LD | 1 |
| Meng, XM | 1 |
| Zhu, DM | 1 |
| Ruan, DY | 1 |
| She, JQ | 1 |
| Luo, L | 1 |
| Coderre, TJ | 1 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Lirng, JF | 1 |
| Chen, JJ | 1 |
| Lodi, R | 1 |
| Pierangeli, G | 1 |
| Tonon, C | 1 |
| Cevoli, S | 1 |
| Testa, C | 1 |
| Bivona, G | 1 |
| Magnifico, F | 1 |
| Cortelli, P | 1 |
| Montagna, P | 1 |
| Barbiroli, B | 1 |
| Gürkan, A | 2 |
| Emingil, G | 2 |
| Atilla, G | 2 |
| Köse, T | 2 |
| Pedersen, A | 1 |
| Rothermundt, M | 1 |
| Schäffler, A | 1 |
| Zeitoun, M | 1 |
| Wobser, H | 1 |
| Buechler, C | 1 |
| Aslanidis, C | 1 |
| Herfarth, H | 1 |
| Han Saygan, B | 1 |
| Baylas, H | 1 |
| Leal, I | 2 |
| Rebolledo, R | 1 |
| Verma, A | 1 |
| Saraswat, VA | 1 |
| Radha Krishna, Y | 1 |
| Nath, K | 1 |
| Thomas, MA | 1 |
| Gupta, RK | 1 |
| Dickstein, DP | 1 |
| van der Veen, JW | 1 |
| Knopf, L | 1 |
| Towbin, KE | 1 |
| Pine, DS | 1 |
| Leibenluft, E | 1 |
| Sarramea Crespo, F | 1 |
| Luque, R | 1 |
| Prieto, D | 1 |
| Sau, P | 1 |
| Albert, C | 1 |
| de Luxan, A | 1 |
| Osuna, MI | 1 |
| Ruiz, M | 1 |
| Galán, R | 1 |
| Cabaleiro, F | 1 |
| Cendes, F | 1 |
| Andermann, F | 2 |
| Silver, K | 1 |
| Arnold, DL | 3 |
| Fujimoto, T | 1 |
| Nakano, T | 1 |
| Takano, T | 1 |
| Takeuchi, K | 1 |
| Yamada, K | 1 |
| Fukuzako, T | 1 |
| Akimoto, H | 1 |
| Kimura, H | 1 |
| Grossman, RI | 1 |
| Gonzalez-Scarano, F | 1 |
| Stanley, JA | 1 |
| Rylett, RJ | 1 |
| Carr, TJ | 1 |
| Malla, A | 1 |
| Thompson, RT | 1 |
| Handa, Y | 1 |
| Kaneko, M | 1 |
| Matuda, T | 1 |
| Kobayashi, H | 1 |
| Kubota, T | 1 |
| Harada, M | 1 |
| Miyoshi, H | 1 |
| Ootsuka, H | 1 |
| Taoka, Y | 1 |
| Tanouchi, M | 1 |
| Nishitani, H | 1 |
| Simpson, MD | 1 |
| Slater, P | 1 |
| Deakin, JF | 1 |
| Raber, J | 1 |
| Bertolino, A | 1 |
| Knable, MB | 1 |
| Saunders, RC | 1 |
| Callicott, JH | 1 |
| Kolachana, B | 1 |
| Mattay, VS | 1 |
| Bachevalier, J | 1 |
| Frank, JA | 1 |
| Egan, M | 1 |
| Weinberger, DR | 1 |
| Li, SJ | 1 |
| Wang, Y | 1 |
| Pankiewicz, J | 1 |
| Stein, EA | 1 |
| Deicken, RF | 1 |
| Pegues, M | 1 |
| Amend, D | 1 |
| Law, RO | 1 |
| Davie, CA | 1 |
| Silver, NC | 1 |
| Barker, GJ | 1 |
| Tofts, PS | 1 |
| Thompson, AJ | 1 |
| McDonald, WI | 1 |
| Miller, DH | 1 |
| Helms, G | 1 |
| Stawiarz, L | 1 |
| Kivisäkk, P | 1 |
| Link, H | 1 |
| Ende, G | 2 |
| Braus, DF | 2 |
| Walter, S | 1 |
| Weber-Fahr, W | 2 |
| Soher, B | 1 |
| Maudsley, AA | 1 |
| Henn, FA | 2 |
| Esquifino, AI | 1 |
| García-Bonacho, M | 1 |
| Castrillón, PO | 1 |
| Duvilanski, BH | 1 |
| Apkarian, VA | 1 |
| Bjartmar, C | 1 |
| Kidd, G | 1 |
| Mörk, S | 1 |
| Rudick, R | 1 |
| Trapp, BD | 1 |
| Rowland, L | 1 |
| Bustillo, JR | 1 |
| Lauriello, J | 1 |
| Villarreal, G | 1 |
| King, CY | 1 |
| Fredickson, BE | 1 |
| Apkarian, AV | 1 |
| Demirakca, T | 1 |
| Tost, H | 1 |
| Lundbom, N | 1 |
| Gaily, E | 1 |
| Vuori, K | 1 |
| Paetau, R | 1 |
| Liukkonen, E | 1 |
| Rajapakse, JC | 1 |
| Valanne, L | 1 |
| Häkkinen, AM | 1 |
| Granström, ML | 1 |
| Köhler, FR | 1 |
| Ebel, J | 1 |
| Prihhodko, VV | 1 |
| Trebler, LIa | 1 |
| Sappey-Marinier, D | 1 |
| Calabrese, G | 1 |
| Hetherington, HP | 1 |
| Fisher, SN | 1 |
| Deicken, R | 1 |
| Van Dyke, C | 1 |
| Fein, G | 1 |
| Weiner, MW | 1 |
| Larsson, HB | 1 |
| Christiansen, P | 1 |
| Jensen, M | 1 |
| Frederiksen, J | 1 |
| Heltberg, A | 1 |
| Olesen, J | 1 |
| Henriksen, O | 1 |
| Janjua, NA | 1 |
| Mori, A | 1 |
| Hiramatsu, M | 1 |
| Matthews, PM | 2 |
| Francis, G | 1 |
| Antel, J | 1 |
| Van Leuven, F | 1 |
| Weyne, J | 1 |
| Smagin, VG | 1 |
| Asafov, GB | 1 |
| Ekisenina, NI | 1 |
| Ivanova, LM | 1 |
| Lumel'skiĭ, VIa | 1 |
| Ripamonti, C | 1 |
| Iencica, R | 3 |
| Gent, AE | 1 |
| Creamer, B | 1 |
| Huth, W | 1 |
| Dierich, C | 1 |
| von Oeynhausen, V | 1 |
| Seubert, W | 1 |
| Fodor, O | 3 |
| Haskell, CM | 1 |
| Canellos, GP | 1 |
| Suciu, A | 1 |
| Szăntay, I | 2 |
| Cotul, S | 2 |
| Szabŏ, P | 2 |
| Melzer, H | 1 |
| Weber, D | 1 |
| Wotzka, R | 1 |
| Bajusz, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exercise Training in Depressed Traumatic Brain Injury Survivors[NCT01805479] | 0 participants (Actual) | Interventional | 2013-02-28 | Withdrawn (stopped due to Unable to enroll participants. Sponsor requested study closure.) | |||
| The Impacts of Yoga and Aerobic Exercise on Neuro-cognitive Function and Symptoms in Early Psychosis - A Single-blind Randomized Controlled Clinical Trial[NCT01207219] | 140 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Physical Exercise Effects on Determinants of Social Integration in Schizophrenia[NCT02716584] | 53 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| Exercise Promotes Neuroplasticity in Depressed and Healthy Brains: An fMRI Pilot Study[NCT03191994] | 40 participants (Anticipated) | Interventional | 2014-01-02 | Recruiting | |||
| Enhancing Synaptic Plasticity and Cognition by Physical Exercise and Cognitive Training in Schizophrenia: A Randomised Controlled Trial[NCT01776112] | 66 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| tDCS for the Management of Chronic Visceral Pain in Patients With Chronic Pancreatitis[NCT01857492] | 0 participants (Actual) | Interventional | 2013-03-31 | Withdrawn (stopped due to Inactive) | |||
| An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS[NCT02587806] | Phase 1/Phase 2 | 69 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitti[NCT02587715] | Phase 1/Phase 2 | 69 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis[NCT02493049] | Phase 2 | 17 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitti[NCT02418325] | Phase 1/Phase 2 | 69 participants (Anticipated) | Interventional | 2015-02-28 | Terminated (stopped due to Lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"measured by Letter Cancellation test Q score. The basic version of the task consists of six 52-character rows in which the target character is randomly interspersed approximately 18 times in each row. Subjects were asked to cancel the letter C and E as quickly as possible. The time to completion, number of error and omission items were recorded. A quality of search index (Q), developed by Geldmacher et al., was applied for the analysis. Q is the ratio of correct number to total number of targets multiplied by the ratio of correct number per second. Higher Q scores represent more efficient performance and better attention and concentration. Q scores could range from 0 (worst possible outcome) to 1 (best possible outcome)." (NCT01207219)
Timeframe: baseline and 12 weeks
| Intervention | Correct number per second (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Aerobic Exercise | 0.71 | 0.77 |
| Waitlist Control Group | 0.74 | 0.73 |
| Yoga Therapy | 0.76 | 0.84 |
PANSS total score is computed by summing the scores of positive, negative and general symptom subscores. The range of PANSS total score is from 30 to 210, range of PANSS positive and negative subscores is from 7 to 49, range of PANSS general symptoms subscore is from 16 to 112, with higher values representing worse outcome. CDS total score is computed by summing the scores of nine items of the scale. The range of CDS total score is from 0 to 27, with higher values representing worse outcome. (NCT01207219)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PANSS total score-Baseline | PANSS total score-12 weeks | PANSS positive subscore-Baseline | PANSS positive subscore-12 weeks | PANSS negative subscore-Baseline | PANSS negative subscore-12 weeks | PANSS general symptoms-Baseline | PANSS general symptoms-12 weeks | CDS-Baseline | CDS-12 weeks | |
| Aerobic Exercise | 46.8 | 39.5 | 9.7 | 8.3 | 11.2 | 9.7 | 25.9 | 21.6 | 3.4 | 1.7 |
| Waitlist Control Group | 45.4 | 49.0 | 9.8 | 10.0 | 11.2 | 12.6 | 24.5 | 26.4 | 3.7 | 4.3 |
| Yoga Therapy | 46.9 | 37.4 | 9.9 | 8.4 | 11.0 | 8.7 | 26.0 | 20.3 | 3.6 | 1.7 |
Total number of corrected encoded words in the first three trials in the random condition of Hong Kong List Learning test. (NCT01207219)
Timeframe: baseline and 12 weeks
| Intervention | correctly encoded words (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Aerobic Exercise | 22.0 | 28.8 |
| Waitlist Control Group | 22.7 | 24.8 |
| Yoga Therapy | 22.8 | 29.5 |
The total number of correctly recalled words after short-term (10 minutes) and long-term (30 minutes) delay in the random condition of Hong Kong List Learning test. (NCT01207219)
Timeframe: baseline and 12 weeks
| Intervention | correctly recorded words (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Aerobic Exercise | 15.1 | 21.0 |
| Waitlist Control Group | 14.5 | 16.6 |
| Yoga Therapy | 14.9 | 19.4 |
measured by Digit Span backwards test. In this test, the subject was asked to recall a series of numbers in reverse order. The correctly recalled series were scored as 1, and the test contains 14 sequences of numbers. The range of working memory score is from 0 to 14, with higher values representing better outcome. (NCT01207219)
Timeframe: baseline and 12 weeks
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Aerobic Exercise | 6.8 | 9.4 |
| Waitlist Control Group | 7.1 | 7.7 |
| Yoga Therapy | 6.8 | 8.5 |
BDNF concentration will be quantified by enzyme-linked immunosorbent assay (R&D Systems). The value will be expressed in ng/ml. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | ng/ml (Mean) |
|---|---|
| Physical Exercise | -1.04 |
| Stretching Exercise | -7.31 |
Raw scores (i.e., total scores) for the following tests will be transformed to z-scores: attention (CPT-IP), speed of processing (BACS symbol coding), working memory (WAIS-IV letter-number sequencing test), verbal learning (Hopkins Verbal Learning Test - Revised), and executive control (AX-CPT). The outcome measure is the mean z-score. The composite z-score indicates the number of standard deviations away from the mean. A z-score of 0 is equal to the mean of the overall sample of study participants. Negative numbers indicate values lower than other study participants and positive numbers indicate values higher than other study participants. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | z-score (Mean) |
|---|---|
| Physical Exercise | .01 |
| Stretching Exercise | .06 |
Raw scores (i.e., total scores) for the following tests will be transformed to z-scores: emotion perception (Facial Emotion Identification Test), social perception (Half-Profile of Nonverbal Sensitivity; PONS), theory of mind (The Awareness of Social Inference Test; TASIT - Part 2), empathy (empathic accuracy test). The outcome measure is the mean z-score. The composite z-score indicates the number of standard deviations away from the mean. A z-score of 0 is equal to the mean of the overall sample of study participants. Negative numbers indicate values lower than other study participants and positive numbers indicate values higher than other study participants. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | z-score (Mean) |
|---|---|
| Physical Exercise | .06 |
| Stretching Exercise | -.17 |
The Brief Psychiatric Rating Scale (BPRS) is a measure of psychiatric symptom severity and includes subscale scores for positive and negative symptoms. The outcome score for negative symptoms is calculated by summing the ratings for items measuring blunted affect, emotional withdrawal, and motor retardation; each item is rated on a scale of 1 to 7 with higher scores indicating greater symptom severity; possible range for negative symptoms is 0 to 21 with higher scores representing greater severity of negative symptoms. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | score on a scale (Mean) |
|---|---|
| Physical Exercise | 0.1 |
| Stretching Exercise | 0.1 |
The Brief Psychiatric Rating Scale (BPRS) is a measure of psychiatric symptom severity and includes subscale scores for positive and negative symptoms. The outcome score for positive symptoms is calculated by summing the ratings for items measuring hallucinations, unusual thought content, and conceptual disorganization; each item is rated on a scale of 1 to 7 with higher scores indicating greater symptom severity; possible range for positive symptoms is 0 to 21 with higher scores representing greater severity of positive symptoms. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | score on a scale (Mean) |
|---|---|
| Physical Exercise | -1.2 |
| Stretching Exercise | -1.2 |
Positive and Negative Affect Scale is a measure of an individual's positive and negative affect. The scale includes 32 items; 16 denote positive affect and 16 denote negative affect. Each item is rated on a scale of 1 (very slightly or not at all) to 5 (extremely). The total score for PANAS negative affect is calculated by summing the ratings for items denoting negative affect. Scores range from 16 to 80; lower scores represent better levels of negative affect. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | score on a scale (Mean) |
|---|---|
| Physical Exercise | 3.8 |
| Stretching Exercise | 2.6 |
Positive and Negative Affect Scale is a measure of an individual's positive and negative affect. The scale includes 32 items; 16 denote positive affect and 16 denote negative affect. Each item is rated on a scale of 1 (very slightly or not at all) to 5 (extremely). The total score for PANAS positive affect is calculated by summing the ratings for items denoting positive affect. Scores range from 16 to 80; higher scores represent better positive affect. (NCT02716584)
Timeframe: Change from baseline to the 12-week endpoint assessment
| Intervention | score on a scale (Mean) |
|---|---|
| Physical Exercise | -5.6 |
| Stretching Exercise | -8.9 |
Birchwood Social Functioning Scale is a measure of social functioning. The total score for social functioning is calculated by summing the raw scores from each of the seven subscales (social engagement, interpersonal communication, independence - performance, independence - competence, recreation, prosocial behavior, employment); possible range is 0 to 223 with higher scores representing better social functioning. (NCT02716584)
Timeframe: Change from baseline to 12 week endpoint assessment
| Intervention | score on a scale (Mean) |
|---|---|
| Physical Exercise | 3.7 |
| Stretching Exercise | -2.5 |
Brief Assessment of Cognition in Schizophrenia (BACS) is a measure of speed of information processing. The total score for speed of processing (i.e., cognition) is calculated by summing the number of symbol-code pairs completed correctly on the BACS Symbol Coding test within the allotted 90 second time limit. Scores range from 0 to 110 with higher scores representing better information processing speed. (NCT02716584)
Timeframe: Change from baseline to 12-week endpoint assessment
| Intervention | score on a scale (Mean) |
|---|---|
| Physical Exercise | -0.4 |
| Stretching Exercise | 2.3 |
Measure of aerobic capacity (VO2max) is derived by using a regression formula based on age, weight, sex, and time to complete walking of one mile. Because scores are derived using a regression equation, there is no absolute minimum or maximum value; higher scores represent better aerobic capacity. (NCT02716584)
Timeframe: Change from baseline to 12-week endpoint assessment
| Intervention | ml.kg-1.min-1 (Mean) |
|---|---|
| Physical Exercise | 4.0 |
| Stretching Exercise | 0.2 |
6 reviews available for aspartic acid and Chronic Disease
| Article | Year |
|---|---|
Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain.
Topics: Amides; Anesthetics, Local; Aspartic Acid; Chronic Disease; Cyclic AMP; Fatigue; Fibromyalgia; Gluta | 2008 |
N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration.
Topics: Adult; Age Factors; Antipsychotic Agents; Aspartic Acid; Choline; Chronic Disease; Creatine; Female; | 2005 |
Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits.
Topics: Acquired Immunodeficiency Syndrome; Adrenocorticotropic Hormone; Amygdala; Animals; Arginine Vasopre | 1998 |
Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia.
Topics: Aspartic Acid; Brain Chemistry; Chronic Disease; Frontal Lobe; Humans; Hydrogen; Magnetic Resonance | 2001 |
Brain imaging in posttraumatic stress disorder.
Topics: Amygdala; Arousal; Aspartic Acid; Atrophy; Brain; Chronic Disease; Cognition; Fear; Hippocampus; Hum | 2001 |
[Some trends in therapy of chronic hepatitis].
Topics: Adrenal Cortex Hormones; Aspartic Acid; Chronic Disease; Diet Therapy; Hepatitis; Humans; Immunosupp | 1968 |
7 trials available for aspartic acid and Chronic Disease
| Article | Year |
|---|---|
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Hippocampal plasticity in response to exercise in schizophrenia.
Topics: Adult; Aspartic Acid; Chronic Disease; Cognition Disorders; Exercise; Hippocampus; Humans; Magnetic | 2010 |
Clinical effects and brain metabolic correlates in non-invasive cortical neuromodulation for visceral pain.
Topics: Adult; Analgesia; Aspartic Acid; Brain; Chronic Disease; Female; Glutamic Acid; Humans; Magnetic Res | 2011 |
Proton magnetic resonance spectroscopy in youth with severe mood dysregulation.
Topics: Antimanic Agents; Arousal; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Bipolar Dis | 2008 |
Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions.
Topics: Acute Disease; Adult; Aged; Aspartic Acid; Brain; Chronic Disease; Contrast Media; Creatine; Female; | 2000 |
[Therapy of acute and chronic hepatitis. A clinical study using Inzolen infusion AM].
Topics: Acute Disease; Aspartic Acid; Chronic Disease; Clinical Trials as Topic; Female; Hepatitis; Humans; | 1979 |
[Controlled clinical trial of a new substance with hepatotropic activity, carried out with an experimental cross-over plan in double-blind conditions].
Topics: Adult; Aged; Alcoholism; Amino Acids; Aspartic Acid; Chemical and Drug Induced Liver Injury; Chronic | 1972 |
[On the therapy of liver diseases with ornithine aspartate].
Topics: Acute Disease; Alanine Transaminase; Ammonia; Aspartic Acid; Bilirubin; Cholangitis; Chronic Disease | 1969 |
78 other studies available for aspartic acid and Chronic Disease
| Article | Year |
|---|---|
Cortical N-acetylaspartate concentrations are impacted in chronic stroke but do not relate to motor impairment: A magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Chronic Disease; Female; Humans; Magnetic Resonance S | 2021 |
Neurochemical changes in the medial wall of the brain in chronic migraine.
Topics: Adult; Aspartic Acid; Brain; Brain Chemistry; Brain Mapping; Chronic Disease; Correlation of Data; C | 2018 |
Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
Topics: Adolescent; Adult; Aspartic Acid; Chronic Disease; Disease Progression; Female; Glutamic Acid; Gluta | 2014 |
Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.
Topics: Adult; AIDS Dementia Complex; Anti-Retroviral Agents; Aspartic Acid; Basal Ganglia; Choline; Chronic | 2014 |
[1H NMR based metabonomics study on the antidepressant effect of genipin in rat hippocampus].
Topics: Alanine; Animals; Antidepressive Agents; Aspartic Acid; Behavior, Animal; Chronic Disease; Depressio | 2014 |
Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.
Topics: Acute Disease; Amino Acids; Animals; Anticonvulsants; Aspartic Acid; Bridged Bicyclo Compounds, Hete | 2014 |
Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and "depressed" mice exposed to chronic mild stress.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Chronic Disease; Depressive Disorder; Disease Models, | 2015 |
Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Choline; Chronic Dise | 2016 |
Proton spectroscopy in patients with post-traumatic headache attributed to mild head injury.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Biomarkers; Brain; Brain Chemistry; Brain Injuries; Brain Ma | 2009 |
Endothelial nitric oxide synthase (eNOS) gene polymorphism in early term chronic allograft nephropathy.
Topics: Adolescent; Aspartic Acid; Chronic Disease; DNA; Exons; Female; Genotype; Glutamine; Guanine; Humans | 2009 |
Elevated gamma-aminobutyric acid levels in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Aspartic Acid; Case-Control Studies; Chronic Disease; Creatine; Female; | 2010 |
[Effect of Chaihu Shugan Tang on excitability in different brain regions of pentylenetetrazole-kindled chronic epileptic rats].
Topics: 4-Chloro-7-nitrobenzofurazan; Animals; Aspartic Acid; Brain; Chronic Disease; Deoxyglucose; Disease | 2010 |
Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartic Acid; | 2010 |
Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients.
Topics: Adult; Age of Onset; Aspartic Acid; Choline; Chronic Disease; Depressive Disorder, Major; Disease Pr | 2011 |
[Study of the Toll-like receptor 4 gene polymorphisms in diseases presenting with subclinical and chronic inflammation].
Topics: Alleles; Aspartic Acid; Brain Ischemia; Chronic Disease; Cytokines; Diabetes Complications; Diabetic | 2011 |
Chronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Behavior, Addictive; Brain Mapping; Case-Control Studies; Ce | 2013 |
Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo ¹H MR spectroscopy at 9.4 T.
Topics: Acute Disease; Algorithms; Animals; Aspartic Acid; Biological Transport, Active; Blood Glucose; Bloo | 2012 |
Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine | 2002 |
Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study.
Topics: Animals; Aspartic Acid; Brain; Brain Ischemia; Chronic Disease; Follow-Up Studies; Immunohistochemis | 2003 |
Association between dorsolateral prefrontal N-acetyl aspartate and depression in chronic back pain: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Back Pain; Chronic Disease; Depression; Female; Humans; Magnetic Resonance Spe | 2003 |
Reversible loss of N-acetyl-aspartate in rats subjected to long-term focal cerebral ischemia.
Topics: Animals; Aspartic Acid; Brain Ischemia; Chromatography, High Pressure Liquid; Chronic Disease; Male; | 2003 |
Proton MR spectroscopic studies of chronic alcohol exposure on the rat brain.
Topics: Alcoholism; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine; Magnetic Resonance Sp | 2003 |
Evaluation of thalamic neural activity in CRPS type 1 patients by proton MR spectroscopy: a correlative study with rCBF.
Topics: Adult; Aspartic Acid; Cerebrovascular Circulation; Chronic Disease; Creatine; Humans; Magnetic Reson | 2003 |
Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Basal Ganglia Diseases; Choline; Chronic Disease; Creati | 2003 |
Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Chronic Disease; Dominance, Cerebral; Female; Glutamic A | 2003 |
A prospective longitudinal in vivo 1H MR spectroscopy study of the SIV/macaque model of neuroAIDS.
Topics: Acute Disease; AIDS Dementia Complex; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creat | 2004 |
Chronic temporal lobe epilepsy: spatial extent and degree of metabolic dysfunction studied with magnetic resonance spectroscopy (MRS).
Topics: Adolescent; Adult; Aspartic Acid; Child; Child, Preschool; Chronic Disease; Creatine; Electroencepha | 2004 |
Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Chronic Disease; Diagnostic and Statistical Manual of Mental Disorders; Female | 2005 |
Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities.
Topics: Adult; Amphetamine-Related Disorders; Aspartic Acid; Basal Ganglia; Brain; Brain Diseases; Choline; | 2005 |
Carbon monoxide brain toxicity: clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Basal Ganglia; Brain; Carbon Monoxide Poisoning; Ch | 2005 |
Effects of chronic lead exposure on 1H MRS of hippocampus and frontal lobes in children.
Topics: Aspartic Acid; Cell Membrane; Cell Survival; Child; Choline; Chronic Disease; Cognition Disorders; C | 2005 |
Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Topics: Amines; Analgesics; Animals; Aspartic Acid; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory | 2005 |
Reduction in hypothalamic 1H-MRS metabolite ratios in patients with cluster headache.
Topics: Adult; Aspartic Acid; Choline; Chronic Disease; Cluster Headache; Creatinine; Diagnosis, Differentia | 2006 |
Study of hypothalamic metabolism in cluster headache by proton MR spectroscopy.
Topics: Acute Disease; Adult; Aged; Aspartic Acid; Biomarkers; Cerebral Cortex; Chronic Disease; Cluster Hea | 2006 |
Endothelial nitric oxide synthase Glu298Asp gene polymorphism in periodontal diseases.
Topics: Acute Disease; Adolescent; Adult; Amino Acid Substitution; Aspartic Acid; Chi-Square Distribution; C | 2006 |
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Antipsychotic Agents; Aspartic Acid; Choline; Chronic Disease; Cognition Disorders; Cre | 2007 |
Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases.
Topics: Amino Acid Substitution; Aspartic Acid; Chronic Disease; Cohort Studies; Cytokines; Diabetes Mellitu | 2007 |
TLR2 Arg753Gly, TLR4 Asp299Gly and Thr399Ile gene polymorphisms are not associated with chronic periodontitis in a Turkish population.
Topics: Adult; Aged; Alleles; Arginine; Aspartic Acid; Case-Control Studies; Chronic Disease; Dental Plaque; | 2007 |
Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Cerebrospinal Fluid; Choline; Chronic Disease; Creatine; Fou | 2007 |
In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Brain; Case-Control Studies; Choline; Chronic Disease; Creat | 2008 |
Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder.
Topics: Adult; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Choline; Chronic Disease; Creatine; Fe | 2008 |
Imaging of axonal damage in vivo in Rasmussen's syndrome.
Topics: Adolescent; Aspartic Acid; Brain Chemistry; Child; Chronic Disease; Creatine; Disease Progression; E | 1995 |
Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia.
Topics: Adult; Aspartic Acid; Basal Ganglia; Basal Ganglia Diseases; Brain Mapping; Choline; Chronic Disease | 1996 |
Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease.
Topics: Adult; Aspartic Acid; Brain; Brain Diseases; Brain Edema; Choline; Chronic Disease; Creatine; Demyel | 1996 |
An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Chronic Disease; Female; Glutamic Acid; Glut | 1996 |
In vivo proton magnetic resonance spectroscopy for metabolic changes in brain during chronic cerebral vasospasm in primates.
Topics: Animals; Aspartic Acid; Brain; Brain Ischemia; Cerebral Angiography; Cerebrovascular Circulation; Ch | 1997 |
[Accuracy and clinical utility of quantitative proton magnetic resonance spectroscopy (MRS) on phantom and chronic cerebral ischemia].
Topics: Aspartic Acid; Brain; Brain Ischemia; Chronic Disease; Creatine; Humans; Magnetic Resonance Spectros | 1997 |
Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia.
Topics: Aged; Aspartic Acid; Chronic Disease; Female; Frontal Lobe; Humans; Male; Middle Aged; Nipecotic Aci | 1998 |
The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia.
Topics: Adult; Animals; Aspartic Acid; Choline; Chronic Disease; Corpus Striatum; Creatinine; Dopamine; Fema | 1999 |
Neurochemical adaptation to cocaine abuse: reduction of N-acetyl aspartate in thalamus of human cocaine abusers.
Topics: Adult; Aspartic Acid; Basal Ganglia; Biomarkers; Brain Chemistry; Case-Control Studies; Choline; Chr | 1999 |
Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia.
Topics: Adult; Aspartic Acid; Cell Death; Chronic Disease; Female; Hippocampus; Humans; Magnetic Resonance I | 1999 |
Amino acid efflux and cell volume regulation in cerebrocortical minislices prepared from chronically hyponatraemic and hypernatraemic rats.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Amino Acids; Animals; Aspartic Acid; Biological Tr | 1999 |
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?
Topics: Aspartic Acid; Axons; Cerebral Cortex; Chronic Disease; Demyelinating Diseases; Disease Progression; | 1999 |
Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Chronic Disease; Clozapine; Creatine; Female; Gyrus Cing | 2000 |
Effect of chronic hyperprolactinemia on daily changes of glutamate and aspartate concentrations in the median eminence and different hypothalamic areas of male rats.
Topics: Animals; Aspartic Acid; Chronic Disease; Circadian Rhythm; Glutamic Acid; Glutamine; Hyperprolactine | 2000 |
Abnormal brain chemistry in chronic back pain: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Anxiety; Aspartic Acid; Back Pain; Brain Chemistry; Choline; Chronic Disease; Creatine; Femal | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Axons; Chronic Disease; Disability Evaluation; Female | 2000 |
Spectroscopic brain mapping the N-acetyl aspartate to cognitive-perceptual states in chronic pain.
Topics: Aspartic Acid; Back Pain; Brain Chemistry; Brain Mapping; Chronic Disease; Cognition; Humans | 2001 |
Dissociating anxiety from pain: mapping the neuronal marker N-acetyl aspartate to perception distinguishes closely interrelated characteristics of chronic pain.
Topics: Anxiety; Aspartic Acid; Brain Chemistry; Brain Mapping; Chronic Disease; Humans; Neurons; Pain | 2001 |
Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Cell Survival; Chronic Disease; Cross-Sectional Studies; | 2002 |
Proton spectroscopic imaging shows abnormalities in glial and neuronal cell pools in frontal lobe epilepsy.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Child; Child, Preschool; Chronic Disease; Creatine; Electro | 2001 |
Decreased levels of N-acetylaspartate in dorsolateral prefrontal cortex in a case of intractable severe sympathetically mediated chronic pain (complex regional pain syndrome, type I).
Topics: Adult; Anxiety Disorders; Aspartic Acid; Chronic Disease; Depressive Disorder, Major; Female; Humans | 2002 |
[Panangin treatment in cardiac insufficiency].
Topics: Aspartic Acid; Chronic Disease; Heart Failure; Humans; Injections, Intravenous; Potassium Magnesium | 1977 |
Proton magnetic resonance spectroscopy of human brain: applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Chemistry; Brain Ischemia; Cerebral Infarction; | 1992 |
Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis.
Topics: Acute Disease; Adult; Aspartic Acid; Brain; Choline; Chronic Disease; Female; Humans; Lipid Metaboli | 1991 |
Increased aspartic acid release from the iron-induced epileptogenic focus.
Topics: Acute Disease; Animals; Aspartic Acid; Chronic Disease; Epilepsy; Glutamates; Glutamic Acid; Iron; M | 1990 |
A proton magnetic resonance spectroscopy study of focal epilepsy in humans.
Topics: Aspartic Acid; Brain; Child; Chronic Disease; Encephalitis; Epilepsies, Partial; Female; Humans; Lac | 1990 |
Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease.
Topics: Aspartic Acid; Brain; Chronic Disease; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectr | 1990 |
Proceedings: Ammonia and amino acids in the brain of the rat with chronic hepatic failure.
Topics: Amino Acids; Ammonia; Animals; Aspartic Acid; Brain; Carbon Tetrachloride Poisoning; Chronic Disease | 1974 |
[Amino acid levels in the blood serum of patients with chronic colitis].
Topics: Adult; Alanine; Amino Acids; Ammonia; Arginine; Aspartic Acid; Betaine; Chronic Disease; Citrulline; | 1974 |
[Effects of treatment with nucleotides and aspartic acid in chronic liver diseases].
Topics: Aspartic Acid; Bilirubin; Chronic Disease; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Nucle | 1972 |
Amino acid homeostasis in the small intestine. II. Studies in man.
Topics: Amino Acids; Aspartic Acid; Celiac Disease; Chronic Disease; Female; Homeostasis; Humans; Intestinal | 1972 |
On the mechanism of ketogenesis and its control. I. On a possible role of acetoacetyl-CoA thiolase in the control of ketone body production.
Topics: Acetates; Acetoacetates; Acetyltransferases; Acute Disease; Animals; Aspartic Acid; Carbon Radioisot | 1973 |
l-asparaginase resistance in human leukemia--asparagine synthetase.
Topics: Acute Disease; Asparaginase; Asparagine; Aspartic Acid; Carbon Isotopes; Chromatography; Chronic Dis | 1969 |
[Urinary elimination of purine and pyrimidine under the therapeutic influence of aspartic acid in chronic hepatitis].
Topics: Aspartic Acid; Chronic Disease; Hepatitis; Humans; Nucleic Acids; Nucleotides; Purines; Pyrimidines | 1972 |
Action of the aspartic acid on the amelioration of hepatic protein synthesis in chronic hepatitis. Study of 75 Se-selenomethionine incorporation in plasma albumins and globulins.
Topics: Aspartic Acid; Blood Proteins; Chronic Disease; Hepatitis; Humans; Liver; Methionine; Methods; Prote | 1972 |
[The action of aspartate on the hepatic and renal fixation of Co58-labeled vitamin B 12 in experimental chronic carbon tetrachloride poisoning].
Topics: Animals; Aspartic Acid; Carbon Tetrachloride Poisoning; Chronic Disease; Cobalt Isotopes; Kidney; Li | 1969 |
Enhanced healing of myocardial lesions and prevention of congestive heart failure. Experimental studies on the therapeutic effect of K-salts, alone and in combination with glucose and insulin, in a hereditary cardiomyopathy.
Topics: Animals; Aspartic Acid; Cardiomyopathies; Chronic Disease; Citrates; Connective Tissue; Cricetinae; | 1969 |